RoosterBio (www.RoosterBio.com) is a Maryland-based biotechnology company founded in 2013 and focused on the simplification of translating cell therapy and tissue engineering technologies into the clinic and onto the market. Regenerative medicine (RegenMed) is showing great promise in the clinic, but the cost, availability, and standardization of the cellular materials from which researchers can perform experiments and clinical trials has been holding the field back.
RoosterBio designs products to accelerate the pace of research and development to help build a robust and sustainable RegenMed industry which will lead to more rapid and wide-spread implementation of life saving therapies. Furthermore, the field of Synthetic Biology is providing a framework from which to begin designing standardized biological components, and we are very interested in marrying the fields of Cell and Tissue Engineering with Synthetic Biology in order to further our cause.
The authors of our blog are experienced leaders in stem cell research, tissue engineering, cell therapy bioprocessing, therapeutic product development, and cell manufacturing operations. We hope to help advance the field of RegeneMed as well as the broader fields of cell-based products and devices by providing robust, high-quality, affordable (cellular) raw materials from which to perform product development experiments. We aim to share the knowledge we have gained over the years with our customers and the greater scientific community via this blog. In this way we believe that we can make our own little “dent in the universe”, and help to accelerate the development of what we are calling the “Cell-based BioEconomy”.
Jon A. Rowley, PhD, is RoosterBio's Founder and Chief Product Officer. Jon founded RoosterBio as part of his personal quest of having the biggest impact possible on the commercial translation of technologies that incorporate living cells, including cellular therapies, engineered tissues, and tomorrow’s medical devices. Jon holds a PhD from the University of Michigan in Biomedical Engineering and has authored over 30 peer reviewed manuscripts and 15 issued or pending patents related to biomaterials development, tissue engineering, and cellular therapy. Jon started his industry career at BD as a scientist and R&D manager in a Cell & Tissue Technologies group focused on applying high throughput screening technologies to cell therapy media development and tissue engineering. Jon then contributed to the clinical development of Aastrom Biosciences’ Tissue Repair Cell product, where he was Sr Manager of Process Development responsible for manufacturing process improvements and cell delivery to the patient. Jon most recently spent 5 years as Director of Innovation and Process Development in Lonza’s Cell Therapy Contract Manufacturing business, and currently resides in Walkersville, MD with his wonderful wife and their 3 young children.